$OSPN

190,621 Shares in Onespan Inc $OSPN Acquired by Deprince Race & Zollo Inc.

Deprince Race & Zollo Inc. acquired 190,621 shares of Onespan Inc (NASDAQ:OSPN) in Q3, valued at approximately $3.03 million, bringing their stake to about 0.50% of the company. Additionally, Director Michael J. McConnell increased his holding by 148% through a purchase of 50,000 shares for $598,000. Analysts currently rate Onespan with a "Moderate Buy" consensus and an average price target of $17.00.

Original reporting
MarketBeat · MarketBeat
Published Dec 29, 2025, 9:33 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Dec 29, 2025, 10:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
190,621 Shares in Onespan Inc $OSPN Acquired by Deprince Race & Zollo Inc. — source image
Decision brief

The 30-second read

$OSPNBullishMed
01

Why it matters

The recent insider purchase and increased institutional stake could signal confidence in the company's growth prospects.

02

Market read

The insider activity and analyst ratings suggest a potential positive shift in stock performance, relevant for traders with a short to medium-term horizon.

03

What to watch

Broader market volatility and company-specific risks could offset positive signals.

Relevance 6/10Timing: Immediate to short-term (next 1-3 months)

Background

Insider activity and analyst ratings suggest a cautiously optimistic outlook for Onespan Inc.

Company-level read

Ticker impact

$OSPNBullishMedium confidence
Context

High relevance due to recent insider trading activity and analyst ratings.

Expected impact

Potential 5-10% increase over the next 1-3 months.

Evidence & confidence

Insider purchases and institutional interest often precede positive stock performance, but broader market conditions and company fundamentals should be considered.

Market effects

Positive sentiment in the financial technology sector, potentially benefiting peers.

Limited regional impact, primarily affecting US-based investors.

Minimal global impact, as the news pertains to a US-listed company.

Counterpoint

Insider buying may be strategic rather than indicative of future performance; caution advised.

Key entities

  • Deprince Race & Zollo Inc.

    A private investment firm that acquired 190,621 shares of OSPN.

  • Michael J. McConnell

    Increased his holdings by 148%, purchasing 50,000 shares.

Related articles

$OSPNMed

OneSpan’s (OSPN) Subscription Growth Masks A Shrinking Bottom Line

OneSpan (OSPN) reported Q2 2026 revenue of $60.5M, up 1% YoY. Subscription revenue grew 11% to $46.7M, while operating income fell 17% to $8.7M. The company raised full-year guidance, expecting $248M-$252M in revenue and $67M-$71M in Adjusted EBITDA. Net income declined to $6.8M, or $0.18 per share, from $8.3M a year earlier.

$OSPNMedAI 8/10

OneSpan (OSPN) Q2 2026 Earnings Call Transcript

OneSpan (OSPN) reported Q2 2026 revenue of $60.5 million, up 1% year over year, with subscription revenue at $46.7 million (+11%) and ARR of $189.7 million (+7%). Adjusted EBITDA was $16.9 million (28% margin). Full-year guidance raised to revenue $248-$252 million and adjusted EBITDA $67-$71 million. The company also launched DigipassONE and returned $2.9 million via repurchases.

$OSPNMed

OneSpan Reports Second Quarter 2026 Financial Results

OneSpan Inc. (OSPN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 OneSpan Reports Second Quarter 2026 Financial Results • Revenue increased 1% year-over-year to $60.5 million • Subscription revenue increased 11% year-over-year to $46.7 million • Operating income decreased 17% year-over-year to $8.7 million • Adjusted EBITDA decreas

$CLYMHighAI 8/10

Climb Bio reports early data on budoprutug for kidney diseases

Climb Bio (CLYM) presented Phase 2 trial data for budoprutug, an anti-CD19 antibody, showing B-cell depletion and PLA2R antibody reductions in kidney disease patients. The 200 mg dose achieved 70% mean antibody reduction, with 5/13 patients in remission. The 600 mg dose showed deeper B-cell depletion. The drug was well-tolerated. Climb Bio expects more data in 2027. Primary membranous nephropathy affects 75,000 people in the U.S. without FDA-approved treatments.